% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{zl:283091,
author = {Özlü, Serap and Dyrba, Martin and Grazia, Alice and
Brosseron, Frederic and Buerger, Katharina and Dechent,
Peter and Düzel, Emrah and Ewers, Michael and Fliessbach,
Klaus and Glanz, Wenzel and Hansen, Niels and
Hellmann-Regen, Julian and Hetzer, Stefan and Janowitz,
Daniel and Kilimann, Ingo and Kronmüller, Marie and Laske,
Christoph and Lüsebrink, Falk and Mengel, David and
Perneczky, Robert and Peters, Oliver and Priller, Josef and
Ramirez, Alfredo and Rauchmann, Boris Stephan and
Rostamzadeh, Ayda and Schneider, Anja and Sodenkamp,
Sebastian and Spottke, Annika and Spruth, Eike Jakob and
Synofzik, Matthis and Wiltfang, Jens and Heneka, Michael T
and Jessen, Frank and Teipel, Stefan},
title = {{CSF} biomarkers of neuroinflammation are associated with
regional atrophy.},
journal = {Journal of neurology},
volume = {273},
number = {1},
issn = {0367-004X},
address = {[Darmstadt]},
publisher = {Steinkopff},
reportid = {DZNE-2025-01498},
pages = {46},
year = {2025},
abstract = {Neuroinflammation is central to Alzheimer's disease (AD)
pathogenesis, yet its contribution to region-specific brain
atrophy remains unclear. We examined whether cerebrospinal
fluid (CSF) biomarkers predict longitudinal atrophy in the
hippocampus and basal forebrain and mediate the impact of AD
pathology.Data from 227 DELCODE participants with baseline
CSF measures and longitudinal structural MRI were analyzed.
Four latent factors (synaptic, microglia,
chemokine/cytokine, complement) were derived to capture
shared variance across biomarkers. Latent factors represent
unobserved biological domains inferred from related CSF
markers. In addition, four single biomarkers (neurogranin,
sTREM2, YKL-40, ferritin) were tested separately. Regional
atrophy rates were estimated using linear mixed-effects
models including biomarker × time, A/T classification,
diagnosis, and covariates (age, sex, education, ApoE-ε4).
Individual slopes were then entered into mediation
models.Higher synaptic latent factor (β = - 0.019, pFDR =
0.021) and YKL-40 (β = - 0.020, pFDR = 0.025) significantly
predicted hippocampal atrophy. Only these two markers
remained significant after correction for multiple
comparisons. Mediation analyses revealed significant
indirect effects of the synaptic latent factor and YKL-40 on
hippocampal atrophy across all A/T groups. No biomarker was
associated with basal forebrain atrophy (pFDR > 0.05).Latent
factors captured shared biological variance across related
biomarkers and provided a more robust representation of
underlying biological domains than single biomarkers. This
approach identified synaptic dysfunction and astroglial
activation as key links between AD pathology and hippocampal
neurodegeneration. These findings highlight synaptic and
glial pathways as promising targets for disease-modifying
interventions.},
keywords = {Humans / Male / Atrophy: pathology / Atrophy: cerebrospinal
fluid / Female / Biomarkers: cerebrospinal fluid / Aged /
Magnetic Resonance Imaging / Hippocampus: pathology /
Hippocampus: diagnostic imaging / Alzheimer Disease:
cerebrospinal fluid / Alzheimer Disease: pathology /
Chitinase-3-Like Protein 1: cerebrospinal fluid /
Neuroinflammatory Diseases: cerebrospinal fluid /
Neuroinflammatory Diseases: pathology / Longitudinal Studies
/ Middle Aged / Aged, 80 and over / Alzheimer’s disease
(Other) / Basal forebrain (Other) / Biomarker (Other) /
Hippocampus (Other) / Neuroinflammation (Other) / Biomarkers
(NLM Chemicals) / Chitinase-3-Like Protein 1 (NLM Chemicals)
/ CHI3L1 protein, human (NLM Chemicals)},
cin = {AG Teipel / AG Heneka / Clinical Research (Munich) / AG
Düzel / Patient Studies (Bonn) / AG Jessen / AG Endres / AG
Spottke / AG Gasser / AG Dichgans / AG Peters / AG Priller /
AG Schneider / ICRU / AG Wiltfang},
ddc = {610},
cid = {I:(DE-2719)1510100 / I:(DE-2719)1011303 /
I:(DE-2719)1111015 / I:(DE-2719)5000006 / I:(DE-2719)1011101
/ I:(DE-2719)1011102 / I:(DE-2719)1811005 /
I:(DE-2719)1011103 / I:(DE-2719)1210000 / I:(DE-2719)5000022
/ I:(DE-2719)5000000 / I:(DE-2719)5000007 /
I:(DE-2719)1011305 / I:(DE-2719)1240005 /
I:(DE-2719)1410006},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41442069},
pmc = {pmc:PMC12738631},
doi = {10.1007/s00415-025-13564-5},
url = {https://pub.dzne.de/record/283091},
}